InsidersTradesSigma
Browse the full management transaction log of OncBioMune Pharmaceuticals, Inc, a listed equity based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 4 February 2016 (Attribution). Among the most active insiders: ELLIOT ROBERT LANGE JR. All data is free.
Analysts rate OncBioMune Pharmaceuticals, Inc Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
5 of 5 declarations
OncBioMune Pharmaceuticals, Inc is a company focused on developing immunotherapeutic treatments for cancer. It aims to enhance treatment options for patients with various types of cancer.